Anheuser Busch Inbev NV ADR (BUD)vsVertex Pharmaceuticals Inc (VRTX)
BUD
Anheuser Busch Inbev NV ADR
$68.06
-0.71%
CONSUMER DEFENSIVE · Cap: $133.23B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Anheuser Busch Inbev NV ADR generates 394% more annual revenue ($59.32B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 11.5%. BUD appears more attractively valued with a PEG of 1.60. VRTX earns a higher WallStSmart Score of 66/100 (B-).
BUD
Buy61
out of 100
Grade: C+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$158.65
Current Price
$68.06
$90.59 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 63.3% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 24.9%
Generating 9.9B in free cash flow
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
4.8% revenue growth
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BUD
The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Revenue Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BUD profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
BUD carries more volatility with a beta of 0.73 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
BUD generates stronger free cash flow (9.9B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 61/100), backed by strong 32.9% margins. BUD offers better value entry with a 51.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?